Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Trastuzumab (Herceptin) and HER2-positive breast cancer

Sally Murray
CMAJ January 03, 2006 174 (1) 36-37; DOI: https://doi.org/10.1503/cmaj.051452
Sally Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.

Background: HER2 (human epidermal growth factor receptor 2) is present in 15%–25% of breast cancers. Women with HER2-positive breast cancer usually have more aggressive cancer, are at increased risk of recurrence and have a poorer survival than other women with breast cancer. Trastuzumab, a recombinant monoclonal antibody, acts against HER2 receptors.

Design: In this international randomized trial, women who had undergone surgical excision of a HER2-positive, early invasive breast cancer and who had completed 4 or more courses of chemotherapy were randomly assigned to receive trastuzumab every 3 weeks or observation alone (control group) for 1 or 2 years. Patients were included if they had adequate liver, kidney and bone marrow function and a normal left ventricular ejection fraction (LVEF). Women were excluded if they had metastases, prior invasive breast cancer, another neoplasm, or a cardiac condition such as angina pectoris requiring medication, uncontrolled hypertension or prior congestive heart failure or myocardial infarction. The primary outcome measure was disease-free survival; secondary end points were cardiac safety, overall survival, time to distant occurrence and site of first disease-free survival event.

Results: The results presented were from an interim analysis of data for women who had been followed for 1 year (1694 in the trastuzumab group, 1693 in the control group). Events (recurrences, new cancer [breast or other], death) were half as common in the treatment group as in the control group (hazard ratio 0.54, 95% confidence interval 0.43– 0.67), although there was no improvement in overall survival in the treatment group. The trastuzumab was stopped in 143 cases (8.5%) because of patient refusal or adverse events. The most common adverse events included congestive heart failure, infection and vascular disorders; serious adverse events occurred more frequently in the treatment group than in the control group (7.9% v. 4.4%).

Commentary: Women with HER2-positive breast cancer in this trial had reduced incidence of cancer recurrence after treatment with trastuzumab, although overall survival did not seem to improve. These findings are similar to postoperative outcomes reported by Romond and colleagues1 and to earlier comparisons of first-line chemotherapy with and without trastuzumab in the treatment of HER2-positive cancers.2,3

Absolute risk reductions (ARRs) shown in Table 1 outline trastuzumab's additional contribution to disease-free survival in 4 published studies. ARRs incorporate information about how likely these events are in this population overall. In this study, 18 women would require treatment with trastuzumab for 1 year for 1 of them to benefit from its use in addition to standard chemotherapy. This number needed to treat is slightly more than that found by Romond and colleagues1 but comparable to that reported in other studies.2,3

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

This benefit needs to be balanced against the adverse events reported. The treatment of 60 women with trastuzumab therapy plus standard chemotherapy in this study would result in 1 patient having symptomatic congestive heart failure. The treatment of only 21 patients (ARR 4.9%) would result in 1 patient having decreased LVEF. Congestive heart failure was even more common in the other studies shown in Table 1,1–3 especially when trastuzumab was given at the same time rather than after standard chemotherapy was finished.2,3

Improved overall survival with the use of trastuzumab to treat HER2-positive breast cancer has also varied between trials (Table 1).

Clinical implications: Data support the use of trastuzumab in women with HER2-positive breast cancer, although unknown factors such as optimum dosing, timing and duration of therapy limit its use. Longer-term outcomes associated with trastuzumab therapy are unknown. Resistance to the drug is now developing as a problem.

The benefits of trastuzumab must be weighed against the drug's known cardiotoxic effects. Women with known cardiac disease were not included in the trials, and trastuzumab cannot be recommended for use in these patients. The risk of congestive heart failure or reduced LVEF in individual patients should be weighed against the likely benefit of treatment and risk of breast cancer recurrence. Future research is also needed to determine the long-term cardiac outcomes among women given trastuzumab.

HER2 testing is not widely available, and trastuzumab is not included on all provincial drug formularies. Women may, however, choose to get trastuzumab treatment in other locations if they have known HER2-positive cancer.

REFERENCES

  1. 1.↵
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med2005; 353(16):1673-84.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265-74.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (1)
CMAJ
Vol. 174, Issue 1
3 Jan 2006
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (117-124)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Trastuzumab (Herceptin) and HER2-positive breast cancer
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Trastuzumab (Herceptin) and HER2-positive breast cancer
Sally Murray
CMAJ Jan 2006, 174 (1) 36-37; DOI: 10.1503/cmaj.051452

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Trastuzumab (Herceptin) and HER2-positive breast cancer
Sally Murray
CMAJ Jan 2006, 174 (1) 36-37; DOI: 10.1503/cmaj.051452
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Management of γ-hydroxybutyrate intoxication and withdrawal
  • Tuberculous monoarthritis of the knee joint
  • Vulvar condyloma lata as a first presentation of syphilis
Show more Practice

Similar Articles

Collections

  • Topics
    • Cancer: breast

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire